Does vraylar have a generic?

When can I expect a generic version of Vraylar?

Vraylar, also known as cariprazine, is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder. As of 2023, Vraylar is a prescription medication sold by Gedeon Richter under an exclusive patent agreement with Allergan.

According to DrugPatentWatch.com [1], the US patent for Vraylar's unique formulation (US Patent 8,557,370) expired in 2022, while the underlying chemistry patent (US Patent 10,333,144) is set to expire in 2026. This means that generic alternatives may start emerging in 2026, depending on regulatory approvals.

What factors may affect the availability of generic Vraylar?

Several factors can influence the development and approval of generic Vraylar:

1. Patent exclusivity: The manufacturer, Gedeon Richter, might have additional patents covering aspects of Vraylar's formulation, manufacturing, or use, potentially delaying generic entry.
2. Regulatory pathways: The FDA (US Food and Drug Administration) may have requirements or timelines that impact the approval process for generic versions.

Who is working on a generic version of Vraylar?

As of now, several pharmaceutical companies are developing generic versions of Vraylar, including Teva Pharmaceuticals and Mylan (now part of Viatris) [2]. These companies have filed Abbreviated New Drug Applications (ANDAs) with the FDA, which are currently under review.

What are the implications for patients and prescribers?

As generic options become available, patients may have more affordable alternatives for treating schizophrenia and bipolar disorder. It's essential for prescribers to stay informed about the generic options and discuss their suitability with patients.